From New York Post · · 50s
Eli Lilly Stock Surges on Weight-Loss Drug Demand
Eli Lilly stock jumps 6% to $1.3 trillion as weight-loss drug sales beat expectations.
In brief
Eli Lilly stock jumps 6% to $1.3 trillion as weight-loss drug sales beat expectations. Eli Lilly's stock hit a record $1.3 trillion valuation after weight-loss drug sales exceeded forecasts by over 5%. Originally reported by New York Post.
Stock Hits Record High
Eli Lilly stock jumped 6% to a record $1.3 trillion valuation after raising full-year earnings forecasts.
Weight-Loss Drug Sales Beat Expectations
Sales of Mounjaro and Zepbound exceeded forecasts by over 5%, solidifying Eli Lilly's lead in the obesity-drug market.
Medicare Patients Using Injections
Over half a million Medicare patients use the injections at a reduced $50-a-month price tag.
Profit Outlook Adjusted Down
The company reduced forecasted profit shares by 50 cents after recent acquisitions of AtaiBeckley and Curevo.
Here's the gist
Eli Lilly's stock hit a record $1.3 trillion valuation after weight-loss drug sales exceeded forecasts by over 5%.
